TY - JOUR
T1 - The potential of circulating exosomal RNA biomarkers in cancer
AU - Chu, Yin Lam
AU - Li, Harriet
AU - Ng, Pik Lan Amanda
AU - Kong, Siu Ting
AU - Zhang, Hao
AU - Lin, Yusheng
AU - Tai, William Chi Shing
AU - Yu, Allen Chi Shing
AU - Yim, Aldrin Kay Yuen
AU - Tsang, Hin Fung
AU - Cho, William Chi Shing
AU - Wong, Sze Chuen Cesar
PY - 2020/4/2
Y1 - 2020/4/2
N2 - Introduction: There are great potentials of using exosomal RNAs (exoRNA) as biomarkers in cancers. The isolation of exoRNA requires the use of ultracentrifugation to isolate cell-free RNA followed by detection using real-time PCR, microarray, next-generation sequencing, or Nanostring nCounter system. The use of exoRNA enrichment panels has largely increased the detection sensitivity and specificity when compared to traditional diagnostic tests. Moreover, using exoRNA as biomarkers can assist the early detection of chemo and radioresistance cancer, and in turn opens up the possibility of personalized treatment to patients. Finally, exoRNA can be detected at an early stage of cancer recurrence to improve the survival rate. Areas covered: In this review, the authors summarized the detection methods of exoRNA as well as its potential as a biomarker in cancer diagnosis and chemo and radioresistance. Expert opinion: The application of exoRNAs in clinical diagnosis is still in its infancy. Further researches on extracellular vesicles isolation, detection protocols, exoRNA classes and subclasses, and the regulatory biological pathways have to be performed before exoRNA can be applied translationally.
AB - Introduction: There are great potentials of using exosomal RNAs (exoRNA) as biomarkers in cancers. The isolation of exoRNA requires the use of ultracentrifugation to isolate cell-free RNA followed by detection using real-time PCR, microarray, next-generation sequencing, or Nanostring nCounter system. The use of exoRNA enrichment panels has largely increased the detection sensitivity and specificity when compared to traditional diagnostic tests. Moreover, using exoRNA as biomarkers can assist the early detection of chemo and radioresistance cancer, and in turn opens up the possibility of personalized treatment to patients. Finally, exoRNA can be detected at an early stage of cancer recurrence to improve the survival rate. Areas covered: In this review, the authors summarized the detection methods of exoRNA as well as its potential as a biomarker in cancer diagnosis and chemo and radioresistance. Expert opinion: The application of exoRNAs in clinical diagnosis is still in its infancy. Further researches on extracellular vesicles isolation, detection protocols, exoRNA classes and subclasses, and the regulatory biological pathways have to be performed before exoRNA can be applied translationally.
KW - cancer monitoring
KW - early detection
KW - exoRNA
KW - Exosomal RNA
KW - noninvasive screening
UR - http://www.scopus.com/inward/record.url?scp=85082929568&partnerID=8YFLogxK
U2 - 10.1080/14737159.2020.1745064
DO - 10.1080/14737159.2020.1745064
M3 - Review article
C2 - 32188269
AN - SCOPUS:85082929568
SN - 1473-7159
VL - 20
SP - 665
EP - 678
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
IS - 7
ER -